Vivanza Biosciences Ltd
Incorporated in 2016, Vivanza Biosciences
Ltd is in the business of Pharmaceutical Products
- Market Cap ₹ 10.8 Cr.
- Current Price ₹ 2.71
- High / Low ₹ 7.20 / 1.90
- Stock P/E
- Book Value ₹ 0.99
- Dividend Yield 0.00 %
- ROCE -2.77 %
- ROE -15.6 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 2.74 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -4.94% over past five years.
- Promoter holding is low: 20.0%
- Company has a low return on equity of 3.85% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 396 days.
- Promoter holding has decreased over last 3 years: -27.8%
- Working capital days have increased from 226 days to 415 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 3.46 | 6.44 | 2.66 | 9.56 | 9.89 | 10.39 | 17.81 | 27.84 | 7.42 | |
0.06 | 3.77 | 5.84 | 2.68 | 9.90 | 9.80 | 10.45 | 17.14 | 26.76 | 7.78 | |
Operating Profit | -0.06 | -0.31 | 0.60 | -0.02 | -0.34 | 0.09 | -0.06 | 0.67 | 1.08 | -0.36 |
OPM % | -8.96% | 9.32% | -0.75% | -3.56% | 0.91% | -0.58% | 3.76% | 3.88% | -4.85% | |
0.00 | 0.04 | 0.00 | 0.00 | 0.57 | 0.51 | 0.83 | 0.48 | 0.05 | 0.06 | |
Interest | 0.00 | 0.04 | 0.37 | 0.42 | 0.44 | 0.47 | 0.43 | 0.43 | 0.42 | 0.35 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
Profit before tax | -0.06 | -0.31 | 0.23 | -0.44 | -0.21 | 0.12 | 0.33 | 0.72 | 0.70 | -0.66 |
Tax % | 0.00% | 0.00% | 13.04% | 0.00% | 0.00% | 41.67% | 0.00% | 16.67% | 21.43% | 1.52% |
-0.06 | -0.31 | 0.21 | -0.44 | -0.21 | 0.08 | 0.33 | 0.60 | 0.55 | -0.67 | |
EPS in Rs | -0.32 | -0.08 | 0.05 | -0.11 | -0.05 | 0.02 | 0.08 | 0.15 | 0.14 | -0.17 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -5% |
3 Years: | -11% |
TTM: | -73% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -222% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | % |
3 Years: | -48% |
1 Year: | -61% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 5% |
3 Years: | 4% |
Last Year: | -16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.19 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
Reserves | -0.16 | -0.47 | -0.27 | -0.71 | -0.92 | -0.84 | -0.51 | 0.09 | 0.64 | -0.04 |
0.50 | 0.90 | 1.32 | 1.48 | 0.39 | 0.36 | 5.51 | 8.00 | 5.17 | 8.65 | |
0.11 | 2.73 | 5.10 | 6.33 | 8.89 | 4.93 | 6.56 | 10.39 | 9.69 | 3.84 | |
Total Liabilities | 0.64 | 7.16 | 10.15 | 11.10 | 12.36 | 8.45 | 15.56 | 22.48 | 19.50 | 16.45 |
0.00 | 2.31 | 2.31 | 2.31 | 2.31 | 2.32 | 2.32 | 2.31 | 2.34 | 2.33 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
0.64 | 4.85 | 7.84 | 8.79 | 10.05 | 6.13 | 13.24 | 20.17 | 17.16 | 14.12 | |
Total Assets | 0.64 | 7.16 | 10.15 | 11.10 | 12.36 | 8.45 | 15.56 | 22.48 | 19.50 | 16.45 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | -2.07 | -0.09 | 0.86 | 2.98 | -3.08 | 2.47 | -0.95 | 2.04 | -2.50 | |
0.00 | 1.90 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | -0.04 | -0.01 | |
0.00 | 0.39 | -0.55 | -0.89 | -2.75 | 2.80 | -2.48 | 1.03 | -1.98 | 2.46 | |
Net Cash Flow | 0.00 | 0.23 | -0.64 | -0.03 | 0.22 | -0.30 | -0.01 | 0.09 | 0.03 | -0.05 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 266.89 | 287.35 | 782.14 | 249.70 | 230.66 | 275.42 | 255.77 | 151.30 | 396.48 | |
Inventory Days | 215.20 | 150.49 | 309.32 | 38.07 | 25.93 | 91.82 | 54.64 | 28.27 | 120.95 | |
Days Payable | 304.36 | 319.46 | 878.47 | 319.47 | 153.98 | 207.06 | 211.26 | 115.76 | 140.22 | |
Cash Conversion Cycle | 177.72 | 118.38 | 212.99 | -31.71 | 102.61 | 160.18 | 99.15 | 63.81 | 377.22 | |
Working Capital Days | 388.21 | 281.12 | 592.78 | 116.07 | 117.36 | 204.81 | 184.86 | 77.09 | 414.68 | |
ROCE % | -10.48% | 12.66% | -0.41% | 5.58% | 16.88% | 12.14% | 10.91% | 10.23% | -2.77% |
Documents
Announcements
-
Newspaper Publication
14 May - Newspaper Publication - The extract of Audited Standalone and Consolidated Financial Results for the Quarter and Financial year ended on March 31, 2025
-
Clarification On Typographical Error
13 May - Correction of meeting date in financial results notes from May 09 to May 12, 2025.
-
Announcement under Regulation 30 (LODR)-Change in Management
12 May - Approved FY25 audited results; appointed internal, secretarial auditors; added independent director; reconstituted board committees.
- Audited Financial Result For The Quarter And Financial Year Ended On 31St March, 2025 12 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today 12Th May, 2025
12 May - Approved FY25 audited results; appointed internal, secretarial auditors; added independent director; reconstituted board committees.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Vivanza Biosciences Limited is a specialty pharma company focused on commercializing novel and generic pharmaceuticals, developing oral drug delivery systems, and having expertise in complex oral and topical dose forms including highly potent compounds, modified release products & injections